![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/5/51/Zanubrutinib.svg/640px-Zanubrutinib.svg.png&w=640&q=50)
Zanubrutinib
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Zanubrutinib?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL).[6][10][11][12][13] Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor.[6] It is given by mouth.[6]
Quick Facts Clinical data, Trade names ...
![]() | |
Clinical data | |
---|---|
Trade names | Brukinsa |
Other names | BGB-3111 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a620009 |
License data |
|
Pregnancy category | |
Routes of administration | By mouth |
Drug class | Bruton's tyrosine kinase (BTK) inhibitor |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
Chemical and physical data | |
Formula | C27H29N5O3 |
Molar mass | 471.561 g·mol−1 |
3D model (JSmol) | |
| |
Close
It was approved for medical use in the United States in November 2019.[14][10][15][16][17]